The chart below shows how NTRA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NTRA sees a -3.60% change in stock price 10 days leading up to the earnings, and a +10.47% change 10 days following the report. On the earnings day itself, the stock moves by +0.73%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Transformational Quarter Highlights: 2024 has already been a transformational year for Natera and I think Q3 represents our best quarter yet.
Record Revenue Growth: We generated $439.8 million in revenue, up 64% from the third quarter of last year, which represents a record quarter for revenue growth.
Volume Growth Surge: Volumes continue to grow rapidly, up 24% year-over-year.
Oncology Test Volume Increase: We performed about 137,000 oncology tests in the quarter, which is up 54% from last year.
Record Gross Margins: Our gross margins were 62% in the quarter, again a record for us.
Negative
Quarterly Revenue Decline: $34.5 million in revenue this quarter, which is lower than last quarter as expected.
Record Gross Margins: The gross margins were 62% in the quarter, again a record for us.
Caution on Future Statements: We caution you that such statements reflect our best judgment based on factors currently known to us and that actual events or results could differ materially.
Weather Impact Analysis: We have seen some modest impact to the weather with the hurricanes hitting like that last week in Q3.
Revenue Forecast Increase: We expect revenues between $1.61 billion and $1.64 billion, which is up roughly $300 million compared to our initial guide this year.
Natera, Inc. (NTRA) Q3 2024 Earnings Call Transcript
NTRA.O
-3.5%